profit from every $100 of sales.
$0$100
SpyGlass Pharma
$32.88-1.32% today
+24.5% since Feb 2, 26
1-year low $17.561-year high $38.37
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What SpyGlass Pharma sold, what it kept, and what it did with the cash.
Sales went from $0 in 2023 to $0 in 2025, with -$39.9 million of profit last year.
SalesProfit
SpyGlass Pharma vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| SpyGlass Pharma | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads SpyGlass Pharma's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| 0 | 0 | 0 | |
| – | – | – | |
| -14 | -27 | -41 | |
| -14 | -27 | -41 | |
| -13 | -29 | -40 | |
| -1.17 | -1.62 | -1.25 | |
| – | – | – | |
| – | – | – | |
| – | – | – |
Balance sheet
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total assets | 41 | 23 | 116 |
| Cash | 16 | 16 | 96 |
| Total debt | 0 | 4 | 2 |
| Total liabilities | 74 | 84 | 215 |
| -33 | -60 | -99 | |
| 11 | 18 | 32 | |
| – | – | – | |
| 40.4% | 48.2% | 40.3% |
Cash flow
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| -12 | -22 | -33 | |
| 0 | 2 | 1 | |
| -12 | -24 | -33 | |
| Dividends paid | – | – | – |
| – | 0 | 1 | |
| 1 | 1 | 3 |
Valuation
- –
- –
- –
- 1.6×
- –
- –
- –
- -3.0%
- -3.6%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -11.5%
- 41.0%
- -123.5%
- -10.2%
- -11.5%
- –
Growth
- –
- –
- –
- –
- –
Financial health
- 8.3×
- 0.01
- 0.6%
- –
- 38.00
- 38.00
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 20%of 963
Bottom 20%of 894
Bottom 21%of 991
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -0.69 | -0.67 | −3.0% |
| Mar 26, 2026 | -5.72 | -0.57 | −896.1% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
36No pass
Benjamin Graham
61Pass
Philip Fisher
42No pass
Peter Lynch
62Pass
Joel Greenblatt
2No pass
Charlie Munger
46No pass
Terry Smith
44No pass
Questions about SpyGlass Pharma
Is SpyGlass Pharma a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the SpyGlass Pharma AI analysis
What does SpyGlass Pharma do?
SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. It is in Biotechnology.
Does SpyGlass Pharma pay a dividend?
No. SpyGlass Pharma does not pay a dividend at the moment; in 2025 it returned $1.45 million to shareholders by buying back its own shares.
Is SpyGlass Pharma stock halal?
Yes. SpyGlass Pharma passes our halal screen: its business is permitted and its debt is 0.1% of its market value, under the 30% limit. How we check
Who are SpyGlass Pharma's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with SpyGlass Pharma's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.